The importance of ensuring an accurate diagnosis of
progressive supranuclear palsy (PSP) is critical for the
development of effective disease-modifying therapies that
are specifically directed at the reduction of tau aggregation
in the pathogenesis of this disorder. Co-authors Tomislav
Babic, MD, PhD, Vice President of Medical and Scientific
Affairs/Neuroscience Franchise and Henry J. Riordan, Ph.D.,
Executive Vice President of Medical and Scientific Affairs
and Global Lead for Neuroscience at Worldwide Clinical

Trials, explain studies regarding the diagnostic criteria of PSP.